The invention concerns fusion proteins, wherein two endoglycosidases are fused, possibly via a linker. The fusion enzymes according to the invention have structure (1): EndoX-(L).sub.p-EndoY (1), wherein EndoX is an endoglycosidase, EndoY is an endoglycosidase distinct from EndoX, L is a linker and p is 0 or 1. Such fusion enzymes capable of trimming glycoproteins comprising at least two distinct glycoforms in a single step. The invention further concerns the use of the fusion enzyme according to the invention for trimming glycoproteins. In another aspect, the invention relates to the process of production of the fusion enzyme. In a further aspect, the inventions concerns a process for trimming glycoproteins, comprising trimming the glycoprotein with a fusion enzyme according to the invention, to obtain a trimmed glycoprotein.

The present invention relates to a conditioning regimen for the transplant of a cell, tissue or organ, optionally hematopoietic stem / progenitor cells, to a subject. The invention also relates to methods for the induction of hematopoietic chimerism in a subject. The invention also relates to methods for the prevention or treatment of a disease or condition in a subject, in which hematopoietic chimerism is induced in order to improve the benefit to the subject of a subsequent therapy. The subsequent therapy may be a cell, tissue or organ transplant or may a gene therapy administered using genetically modified hematopoietic stem cells/progenitor cells.

The present invention relates to compositions such as cleaning compositions comprising a mix of enzymes. The invention further relates, use of compositions comprising such enzymes in cleaning processes.

Provided herein are deglycosylating enzymes that remove a broad range of N-glycans from N-glycosylated proteins. Further provided are methods of recombinantly producing and expressing the deglycosylating enzymes. The presently described deglycosylating enzymes can be used to produce free glycans for characterization, and for prebiotic and immunostimulatory uses. In addition, the presently described deglycosylating enzymes can be used to produce deglycosylated proteins for characterization, to improve digestion, and to reduce immunogenicity.

The present invention provides for recombinant Endo-D and selected mutants that exhibit reduced hydrolysis activity and increased transglycosylation activity for the synthesis of glycoproteins wherein a desired sugar chain is added to a core fucosylated or nonfucosylated GlcNAc-protein acceptor by transglycosylation. Such recombinant Endo-D and selected mutants are useful for efficient glycosylation remodeling of IgG1-Fc domain.

The present invention provides methods for producing scaffolded (e.g., nanoparticle presented) or non-scaffolded vaccines that are based on viral immunogenic proteins with a glycan shielded (e.g., HIV-1 Env). The vaccines thus generated demonstrate enhanced immunogenicity and responder frequency. The methods entail (1) enzymatic digestion of glycan chain on the surface of a viral trimer protein immunogen or a self-assembling nanoparticle vaccine displaying the viral immunogen (e.g., an HIV-1 UFO trimer), or (2) expression of a construct encoding the vaccine in an expression system lacking normal glycosylation function for human proteins. Also provided in the invention are vaccine compositions produced with the described methods. The invention further provides methods of using the vaccine compositions described herein (e.g., scaffolded or non-scaffolded HIV-1 vaccines) in various therapeutic applications, e.g., for preventing or treating viral infections.

The invention relates to compositions comprising therapeutic antibodies, and uses and methods for increasing the potency of therapeutic antibodies. In particular, the invention provides a composition comprising (i) an agent which reduces Fc receptor binding of endogenous serum antibodies, and (ii) a therapeutic antibody, preferably a therapeutic antibody which is resistant to the agent. The therapeutic antibody may be administered to the subject after a set time interval, or the blood of the subject may be treated with the agent prior to administration of the therapeutic antibody.

The present invention provides a novel endo-β-N-acetylglucosaminidase that is isolated from a fungus belonging to the genus Rhizomucor and is active under high-temperature conditions; various mutant enzymes thereof; genes encoding the enzymes; a recombinant plasmid; a transformant transformed with the plasmid; and the like.

Provided herein are compositions with enhanced protein content, proteins with high solubility, protein combinations and methods for the preparation thereof.

Disclosed is a method for producing a glycoprotein using mammalian cells, wherein all or part of the non-reducing ends of N-glycoside binding sugar chains are mannose residues. The method is a method for producing glycoproteins using transformant mammalian cells which are prepared by introducing thereinto a β-N-acetylglucosaminidase gene and inducing its expression.